Effects of Bilberry and Oat intake on lipids, inflammation and exercise capacity after Acute Myocardial Infarction (BIOAMI): study protocol for a randomized, double-blind, placebo-controlled trial

Cecilia Bergh, Rikard Landberg, Kristina Andersson, Lovisa Heyman-Lindén, Ana Rascón, Anders Magnuson, Payam Khalili, Amra Kåregren, Johan Nilsson, Carlo Pirazzi, David Erlinge, Ole Fröbert, Cecilia Bergh, Rikard Landberg, Kristina Andersson, Lovisa Heyman-Lindén, Ana Rascón, Anders Magnuson, Payam Khalili, Amra Kåregren, Johan Nilsson, Carlo Pirazzi, David Erlinge, Ole Fröbert

Abstract

Background: Bilberries from Sweden, rich in polyphenols, have shown cholesterol-lowering effects in small studies, and the cholesterol-lowering properties of oats, with abundant beta-glucans and potentially bioactive phytochemicals, are well established. Both may provide cardiometabolic benefits following acute myocardial infarction (AMI), but large studies of adequate statistical power and appropriate duration are needed to confirm clinically relevant treatment effects. No previous study has evaluated the potential additive or synergistic effects of bilberry combined with oats on cardiometabolic risk factors. Our primary objective is to assess cardioprotective effects of diet supplementation with dried bilberry or with bioprocessed oat bran, with a secondary explorative objective of assessing their combination, compared with a neutral isocaloric reference supplement, initiated within 5 days following percutaneous coronary intervention (PCI) for AMI.

Methods: The effects of Bilberry and Oat intake on lipids, inflammation and exercise capacity after Acute Myocardial Infarction (BIOAMI) trial is a double-blind, randomized, placebo-controlled clinical trial. A total of 900 patients will be randomized post-PCI to one of four dietary intervention arms. After randomization, subjects will receive beverages with bilberry powder (active), beverages with high-fiber bioprocessed oat bran (active), beverages with bilberry and oats combined (active), or reference beverages containing no active bilberry or active oats, for consumption twice daily during a 3-month intervention. The primary endpoint is the difference in LDL cholesterol change between the intervention groups after 3 months. The major secondary endpoint is exercise capacity at 3 months. Other secondary endpoints include plasma concentrations of biochemical markers of inflammation, metabolomics, and gut microbiota composition after 3 months.

Discussion: Controlling hyperlipidemia and inflammation is critical to preventing new cardiovascular events, but novel pharmacological treatments for these conditions are expensive and associated with negative side effects. If bilberry and/or oat, in addition to standard medical therapy, can lower LDL cholesterol and inflammation more than standard therapy alone, this could be a cost-effective and safe dietary strategy for secondary prevention after AMI.

Trial registration: ClinicalTrials.gov NCT03620266 . Registered on August 8, 2018.

Keywords: Anthocyanin; Anthocyanin-derived phenolic acid metabolites; Bilberry; Cholesterol; Diet therapy; Exercise test; Inflammation; Myocardial infarction.

Conflict of interest statement

KA and AR are, apart from their academic activities, also Senior Scientist and CSO, respectively, at Glucanova AB. AR, KA, and LHL are involved in the study product conceptualization, development, and production but not in data collection or data analysis.

Figures

Fig. 1
Fig. 1
Flowchart of study design. AMI, acute myocardial infarction; PCI, percutaneous coronary intervention
Fig. 2
Fig. 2
SPIRIT figure of the trial procedure including enrolment, data collection, intervention, and assessments

References

    1. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937–952. doi: 10.1016/S0140-6736(04)17018-9.
    1. Kaptoge S, Seshasai SR, Gao P, Freitag DF, Butterworth AS, Borglykke A, et al. Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis. Eur Heart J. 2014;35(9):578–589. doi: 10.1093/eurheartj/eht367.
    1. Bergh C, Fall K, Udumyan R, Sjoqvist H, Frobert O, Montgomery S. Severe infections and subsequent delayed cardiovascular disease. Eur J Prev Cardiol. 2017;24(18):1958–1966. doi: 10.1177/2047487317724009.
    1. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation. 2010;121(7):e46–e215. doi: 10.1161/CIRCULATIONAHA.109.192667.
    1. Sabatine MS, Wiviott SD, Im K, Murphy SA, Giugliano RP. Efficacy and safety of further lowering of low-density lipoprotein cholesterol in patients starting with very low levels: a meta-analysis. JAMA Cardiol. 2018;3(9):823–828. doi: 10.1001/jamacardio.2018.2258.
    1. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC, Jr, Sperling L, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):e285–e350. doi: 10.1016/j.jacc.2018.11.003.
    1. Weintraub WS, Gidding SS. PCSK9 inhibitors: a technology worth paying for? Pharmacoeconomics. 2016;34(3):217–220. doi: 10.1007/s40273-015-0355-y.
    1. Chen ZY, Jiao R, Ma KY. Cholesterol-lowering nutraceuticals and functional foods. J Agric Food Chem. 2008;56(19):8761–8773. doi: 10.1021/jf801566r.
    1. Briffa TG, Hobbs MS, Tonkin A, Sanfilippo FM, Hickling S, Ridout SC, Knuiman M. Population trends of recurrent coronary heart disease event rates remain high. Circ Cardiovasc Qual Outcomes. 2011;4(1):107–113. doi: 10.1161/CIRCOUTCOMES.110.957944.
    1. Smith SC, Jr, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. J Am Coll Cardiol. 2011;58(23):2432–2446. doi: 10.1016/j.jacc.2011.10.824.
    1. Adamsson V, Reumark A, Fredriksson IB, Hammarstrom E, Vessby B, Johansson G, et al. Effects of a healthy Nordic diet on cardiovascular risk factors in hypercholesterolaemic subjects: a randomized controlled trial (NORDIET) J Intern Med. 2011;269(2):150–159. doi: 10.1111/j.1365-2796.2010.02290.x.
    1. Uusitupa M, Hermansen K, Savolainen MJ, Schwab U, Kolehmainen M, Brader L, Mortensen LS, Cloetens L, Johansson-Persson A, Önning G, Landin-Olsson M, Herzig KH, Hukkanen J, Rosqvist F, Iggman D, Paananen J, Pulkki KJ, Siloaho M, Dragsted L, Barri T, Overvad K, Bach Knudsen KE, Hedemann MS, Arner P, Dahlman I, Borge GIA, Baardseth P, Ulven SM, Gunnarsdottir I, Jónsdóttir S, Thorsdottir I, Orešič M, Poutanen KS, Risérus U, Åkesson B. Effects of an isocaloric healthy Nordic diet on insulin sensitivity, lipid profile and inflammation markers in metabolic syndrome -- a randomized study (SYSDIET) J Intern Med. 2013;274(1):52–66. doi: 10.1111/joim.12044.
    1. Rodriguez-Mateos A, Istas G, Boschek L, Feliciano RP, Mills CE, Boby C, Gomez-Alonso S, Milenkovic D, Heiss C. Circulating anthocyanin metabolites mediate vascular benefits of blueberries: insights from randomized controlled trials, metabolomics, and nutrigenomics. J Gerontol A Biol Sci Med Sci. 2019;74(7):967–976. doi: 10.1093/gerona/glz047.
    1. Ioannidis JPA. The challenge of reforming nutritional epidemiologic research. JAMA. 2018;320(10):969–970. doi: 10.1001/jama.2018.11025.
    1. Chan SW, Tomlinson B. Effects of bilberry supplementation on metabolic and cardiovascular disease risk. Molecules. 2020;25(7).
    1. Ho HV, Sievenpiper JL, Zurbau A, Blanco Mejia S, Jovanovski E, Au-Yeung F, et al. The effect of oat beta-glucan on LDL-cholesterol, non-HDL-cholesterol and apoB for CVD risk reduction: a systematic review and meta-analysis of randomised-controlled trials. Br J Nutr. 2016;116(8):1369–1382. doi: 10.1017/S000711451600341X.
    1. Pavadhgul P, Bumrungpert A, Harjani Y, Kurilich A. Oat porridge consumption alleviates markers of inflammation and oxidative stress in hypercholesterolemic adults. Asia Pac J Clin Nutr. 2019;28(2):260–265. doi: 10.6133/apjcn.201906_28(2).0008.
    1. Huang H, Chen G, Liao D, Zhu Y, Xue X. Effects of berries consumption on cardiovascular risk factors: a meta-analysis with trial sequential analysis of randomized controlled trials. Sci Rep. 2016;6(1):23625. doi: 10.1038/srep23625.
    1. Wang X, Ouyang YY, Liu J, Zhao G. Flavonoid intake and risk of CVD: a systematic review and meta-analysis of prospective cohort studies. Br J Nutr. 2014;111(1):1-11, 1, DOI: 10.1017/S000711451300278X.
    1. McCullough ML, Peterson JJ, Patel R, Jacques PF, Shah R, Dwyer JT. Flavonoid intake and cardiovascular disease mortality in a prospective cohort of US adults. Am J Clin Nutr. 2012;95(2):454–464. doi: 10.3945/ajcn.111.016634.
    1. Grosso G, Micek A, Godos J, Pajak A, Sciacca S, Galvano F, Giovannucci EL. Dietary flavonoid and lignan intake and mortality in prospective cohort studies: systematic review and dose-response meta-analysis. Am J Epidemiol. 2017;185(12):1304–1316. doi: 10.1093/aje/kww207.
    1. Bondonno NP, Dalgaard F, Kyro C, Murray K, Bondonno CP, Lewis JR, et al. Flavonoid intake is associated with lower mortality in the Danish Diet Cancer and Health Cohort. Nat Commun. 2019;10(1):3651. doi: 10.1038/s41467-019-11622-x.
    1. Habanova M, Saraiva JA, Haban M, Schwarzova M, Chlebo P, Predna L, et al. Intake of bilberries (Vaccinium myrtillus L.) reduced risk factors for cardiovascular disease by inducing favorable changes in lipoprotein profiles. Nutr Res (New York, NY) 2016;36(12):1415–1422. doi: 10.1016/j.nutres.2016.11.010.
    1. Erlund I, Koli R, Alfthan G, Marniemi J, Puukka P, Mustonen P, Mattila P, Jula A. Favorable effects of berry consumption on platelet function, blood pressure, and HDL cholesterol. Am J Clin Nutr. 2008;87(2):323–331. doi: 10.1093/ajcn/87.2.323.
    1. Lynn A, Garner S, Nelson N, Simper TN, Hall AC, Ranchordas MK. Effect of bilberry juice on indices of muscle damage and inflammation in runners completing a half-marathon: a randomised, placebo-controlled trial. J Int Soc Sports Nutr. 2018;15(1):22. doi: 10.1186/s12970-018-0227-x.
    1. Yarahmadi M, Askari G, Kargarfard M, Ghiasvand R, Hoseini M, Mohamadi H, Asadi A. The effect of anthocyanin supplementation on body composition, exercise performance and muscle damage indices in athletes. Int J Prev Med. 2014;5(12):1594–1600.
    1. Arevstrom L, Bergh C, Landberg R, Wu H, Rodriguez-Mateos A, Waldenborg M, et al. Freeze-dried bilberry (Vaccinum myrtillus) dietary supplement improves walking distance and lipids after myocardial infarction. An open-label randomized clinical trial. Nutr Res. 2018;62:3–22.
    1. Hanhineva K, Lankinen MA, Pedret A, Schwab U, Kolehmainen M, Paananen J, de Mello V, Sola R, Lehtonen M, Poutanen K, Uusitupa M, Mykkänen H. Nontargeted metabolite profiling discriminates diet-specific biomarkers for consumption of whole grains, fatty fish, and bilberries in a randomized controlled trial. J Nutr. 2015;145(1):7–17. doi: 10.3945/jn.114.196840.
    1. Feliciano RP, Mecha E, Bronze MR, Rodriguez-Mateos A. Development and validation of a high-throughput micro solid-phase extraction method coupled with ultra-high-performance liquid chromatography-quadrupole time-of-flight mass spectrometry for rapid identification and quantification of phenolic metabolites in human plasma and urine. J Chromatogr A. 2016;1464:21–31. doi: 10.1016/j.chroma.2016.08.027.
    1. Pridal AA, Böttger W, Ross AB. Analysis of avenanthramides in oat products and estimation of avenanthramide intake in humans. Food Chem. 2018;253:93–100. doi: 10.1016/j.foodchem.2018.01.138.
    1. Brunius C, Shi L, Landberg R. Large-scale untargeted LC-MS metabolomics data correction using between-batch feature alignment and cluster-based within-batch signal intensity drift correction. Metabolomics. 2016;12(11):173. doi: 10.1007/s11306-016-1124-4.
    1. Sing R, Chandrashekharappa S, Bodduluri S, Baby B, Hedge B, Kotla N, et al. Enhancement of the gut barrier integrity by a microbia metabolite through the Nrf2 pathway. Nat Commun. 2019;10(89):1–18.
    1. Shi L, Brunius C, Lindelof M, Shameh SA, Wu H, Lee I, et al. Targeted metabolomics reveals differences in the extended postprandial plasma metabolome of healthy subjects after intake of whole-grain rye porridges versus refined wheat bread. Mol Nutr Food Res. 2017;61(7).
    1. Hellmark M, Bäck M. Test-retest reliability and responsiveness to change of clinical tests of physical fitness in patients with acute coronary syndrome included in the SWEDEHEART register. Eur J Cardiovasc Nurs. 2018;17(6):486–95. 10.1177/1474515117743978. Epub 2017 Dec 1.
    1. Exercise test in relation to cardiovascular function. Report of a WHO meeting. World Health Organ Tech Rep Ser. 1968;388:1–30.
    1. Borg G. Ratings of perceived exertion and heart rates during short-term cycle exercise and their use in a new cycling strength test. Int J Sports Med. 1982;3(3):153–158. doi: 10.1055/s-2008-1026080.
    1. Borg G. Borg’s perceived exertion and pain scales. Champaigne, IL, US: Human Kinetics; 1998.
    1. Michelsen S. Reproducibility of cumulative work, heart rate and blood pressure response during stepwise versus continuous load increment during a maximal bicycle ergometer test. Scand J Clin Lab Invest. 1990;50(4):409–415. doi: 10.3109/00365519009091599.
    1. Streiner DL, Norman GR, Cairney J. Health measurement scales: a practical guide to their development and use. 2. Oxford: Oxford University Press; 2015.
    1. Cider A, Carlsson S, Arvidsson C, Andersson B, Sunnerhagen KS. Reliability of clinical muscular endurance tests in patients with chronic heart failure. Eur J Cardiovasc Nurs. 2006;5(2):122–126. doi: 10.1016/j.ejcnurse.2005.10.001.
    1. Ainsworth BE, Haskell WL, Whitt MC, Irwin ML, Swartz AM, Strath SJ, et al. Compendium of physical activities: an update of activity codes and MET intensities. Med Sci Sports Exerc. 2000;32(9 Suppl):S498–S504. doi: 10.1097/00005768-200009001-00009.
    1. Grimby G, Frandin K. On the use of a six-level scale for physical activity. Scand J Med Sci Sports. 2018;28(3):819–825. doi: 10.1111/sms.12991.
    1. Harris H, Håkansson N, Olofsson C, Stackelberg O, Julin B, Åkesson A. The Swedish mammography cohort and the cohort of Swedish men: study design and characteristics of two population-based longitudinal cohorts. OA Epidemiol. 2013;1(2):16. doi: 10.13172/2053-079X-1-2-943.
    1. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, de Ferrari GM, Ruzyllo W, de Lucca P, Im KA, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387–2397. doi: 10.1056/NEJMoa1410489.
    1. Hanhineva K, Brunius C, Andersson A, Marklund M, Juvonen R, Keski-Rahkonen P, Auriola S, Landberg R. Discovery of urinary biomarkers of whole grain rye intake in free-living subjects using nontargeted LC-MS metabolite profiling. Mol Nutr Food Res. 2015;59(11):2315–2325. doi: 10.1002/mnfr.201500423.
    1. Kolehmainen M, Mykkanen O, Kirjavainen PV, Leppanen T, Moilanen E, Adriaens M, et al. Bilberries reduce low-grade inflammation in individuals with features of metabolic syndrome. Mol Nutr Food Res. 2012;56(10):1501–10. doi: 10.1002/mnfr.201200195.
    1. Andersson KE, Hellstrand P. Dietary oats and modulation of atherogenic pathways. Mol Nutr Food Res. 2012;56(7):1003–1013. doi: 10.1002/mnfr.201100706.
    1. Andersson KE, Svedberg KA, Lindholm MW, Oste R, Hellstrand P. Oats (Avena sativa) reduce atherogenesis in LDL-receptor-deficient mice. Atherosclerosis. 2010;212(1):93–99. doi: 10.1016/j.atherosclerosis.2010.05.001.
    1. Landberg R, Sunnerheim K, Dimberg LH. Avenanthramides as lipoxygenase inhibitors. Heliyon. 2020;6(6):e04304. doi: 10.1016/j.heliyon.2020.e04304.
    1. Liu L, Zubik L, Collins FW, Marko M, Meydani M. The antiatherogenic potential of oat phenolic compounds. Atherosclerosis. 2004;175(1):39–49. doi: 10.1016/j.atherosclerosis.2004.01.044.
    1. Nie L, Wise ML, Peterson DM, Meydani M. Avenanthramide, a polyphenol from oats, inhibits vascular smooth muscle cell proliferation and enhances nitric oxide production. Atherosclerosis. 2006;186(2):260–266. doi: 10.1016/j.atherosclerosis.2005.07.027.
    1. Cassidy A, Mukamal KJ, Liu L, Franz M, Eliassen AH, Rimm EB. High anthocyanin intake is associated with a reduced risk of myocardial infarction in young and middle-aged women. Circulation. 2013;127(2):188–196. doi: 10.1161/CIRCULATIONAHA.112.122408.
    1. Cassidy A, O'Reilly EJ, Kay C, Sampson L, Franz M, Forman JP, et al. Habitual intake of flavonoid subclasses and incident hypertension in adults. Am J Clin Nutr. 2011;93(2):338–347. doi: 10.3945/ajcn.110.006783.
    1. Curtis PJ, van der Velpen V, Berends L, Jennings A, Feelisch M, Umpleby AM, Evans M, Fernandez BO, Meiss MS, Minnion M, Potter J, Minihane AM, Kay CD, Rimm EB, Cassidy A. Blueberries improve biomarkers of cardiometabolic function in participants with metabolic syndrome-results from a 6-month, double-blind, randomized controlled trial. Am J Clin Nutr. 2019;109(6):1535–1545. doi: 10.1093/ajcn/nqy380.
    1. Feldman DN, Kim L, Rene AG, Minutello RM, Bergman G, Wong SC. Prognostic value of cardiac troponin-I or troponin-T elevation following nonemergent percutaneous coronary intervention: a meta-analysis. Catheter Cardiovasc Interv. 2011;77(7):1020–1030. doi: 10.1002/ccd.22962.
    1. Shugman IM, Diu P, Gohil J, Kadappu KK, Leung M, Lo S, Leung DY, Hopkins AP, Juergens CP, French JK. Evaluation of troponin T criteria for periprocedural myocardial infarction in patients with acute coronary syndromes. Am J Cardiol. 2011;107(6):863–870. doi: 10.1016/j.amjcard.2010.11.007.
    1. Muller D, Schantz M, Richling E. High performance liquid chromatography analysis of anthocyanins in bilberries (Vaccinium myrtillus L.), blueberries (Vaccinium corymbosum L.), and corresponding juices. J Food Sci. 2012;77(4):C340–C345. doi: 10.1111/j.1750-3841.2011.02605.x.
    1. Trpkovic A, Resanovic I, Stanimirovic J, Radak D, Mousa SA, Cenic-Milosevic D, Jevremovic D, Isenovic ER. Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases. Crit Rev Clin Lab Sci. 2015;52(2):70–85. doi: 10.3109/10408363.2014.992063.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj